GPCR

Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics Inc. American Depositary Shares (GPCR) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -13.5
Rev Growth YoY 0.0%
Gross Margin N/A
Price Return 3M 15.3%
Price Return 12M 182.2%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.0
ROE -15.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C (2.3) C+ (2.8) C (2.4) C- (1.9) C (2.4)
2026-08-04 C+ (2.7) C (2.3) C+ (2.8) C (2.4) C- (1.9) C (2.5)
2026-08-03 C+ (2.7) C (2.4) C- (2.1) C (2.4) C- (2.0) C (2.3)
2026-08-02 C+ (2.7) C (2.4) C- (2.1) C (2.4) C- (1.9) C (2.3)